475 Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells

475 Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells

Bibliographic Details
Main Authors:	Paul Foster, Amita Patnaik, Lisa Seitz, Dana Piovesan, Soonweng Cho, Xiaoning Zhao, Amy E Anderson, Nigel Walker, Hema Singh, Casey G Mitchell, Matthew J Walters, Kelsey E Sivick Gauthier, Amber E de Groot, Rebecca D Ray, Nina K Serwas
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity
by: Alyson J. Smith, et al.
Published: (2023-11-01)

479 Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models
by: Xin Zhang, et al.
Published: (2023-11-01)

Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response
by: Riyao Yang, et al.
Published: (2023-06-01)

Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies
by: Dean A Lee, et al.
Published: (2023-12-01)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
by: Jinah Yeo, et al.
Published: (2021-02-01)

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
by: Brazel D, et al.
Published: (2023-01-01)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
by: Marina Martinez, et al.
Published: (2021-01-01)

485 TIGIT/PVRIG humanized mice-an idea model for studying anti-PVRIG antibodies
by: Xiang Gao, et al.
Published: (2023-11-01)

Anti-epileptogenic effect of FC99 and resveratrol
by: Oded Shor, et al.
Published: (2023-08-01)

TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies
by: Md Faqrul Hasan, et al.
Published: (2023-05-01)

P475: CONTROL LEUKEMIA BY INDUCING ANTI-CANCER IMMUNE REACTIVITY IN VIVO? POTENTIAL OF A DC-TRIGGERED MECHANISM
by: G. Filippini Velazquez, et al.
Published: (2022-06-01)

A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
by: Shiran Hoogi, et al.
Published: (2019-09-01)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01)

Anti-Diabetic Activity of Glycyrrhetinic Acid Derivatives FC-114 and FC-122: Scale-Up, In Silico, In Vitro, and In Vivo Studies
by: Samuel Álvarez-Almazán, et al.
Published: (2023-08-01)

74 a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME)
by: Maurizio Ceppi, et al.
Published: (2023-11-01)

Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells
by: Marenori Kojima, et al.
Published: (2023-05-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)

Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection against Streptococcus pneumoniae
by: Leire Aguinagalde Salazar, et al.
Published: (2023-03-01)

475 Financial Toxicity in Dementia Caregiving
by: Danielle M. Hart, et al.
Published: (2023-04-01)

FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
by: Isabell Lang, et al.
Published: (2022-10-01)

ImmunoPET imaging of TIGIT in the glioma microenvironment
by: Sarah R. Vincze, et al.
Published: (2024-03-01)

PP 8.5 – 00080 Fc-engineering of anti-HIV-1 antibodies and nanobodies to improve Fc mediated effector functions
by: A. Schriek, et al.
Published: (2022-12-01)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2023-06-01)

511 Activity of anti-CD47 antibodies is enhanced through Fc optimization
by: Patrick Smith, et al.
Published: (2023-11-01)

Role of Homologous Fc Fragment in the Potency and Efficacy of Anti‐Botulinum Antibody Preparations
by: Amram Torgeman, et al.
Published: (2017-05-01)

1385 Dual Inhibition of DGKα and DGKζ increases T cell and NK cell activity
by: Ning Wang, et al.
Published: (2023-11-01)

TIGIT in Lung Cancer: Potential Theranostic Implications
by: Carlo Pescia, et al.
Published: (2023-04-01)

The landscape of TIGIT target and clinical application in diseases
by: Shu Rui, et al.
Published: (2022-09-01)

Circulating TIGIT±PD1+TPH, TIGIT ± PD1+TFH cells are elevated and their predicting role in systemic lupus erythematosus
by: Qing Luo, et al.
Published: (2024-03-01)

BOO 475-2 - SITOLOGI & SITOGENETIK NOV. 1988.
by: PPSKJ, Pusat Pengajian Sains Kajihayat
Published: (1988)

AMR affects Asia 4.75 million people
by: China Press
Published: (2023)

PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash
by: X Huang, et al.
Published: (2022-10-01)

TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
by: Friedrich Haag, et al.
Published: (2022-12-01)

Síndrome del seno silente Silent sinus syndrome
by: Ricardo Trueba, et al.
Published: (2008-03-01)

Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer
by: Yun Hu, et al.
Published: (2022-09-01)

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
by: Kate J. Dixon, et al.
Published: (2021-01-01)

Correlation of Anti-HLA IgA Alloantibodies and Fc Receptor Motives with Kidney Allograft Survival
by: Marie-Luise Arnold, et al.
Published: (2022-04-01)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
by: Anand Rotte, et al.
Published: (2021-09-01)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
by: Yuanyuan Zha, et al.
Published: (2023-06-01)

TIGIT, a novel immune checkpoint therapy for melanoma
by: Wei Tang, et al.
Published: (2023-07-01)